Clinical Trial Update: Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating utidelone and anlotinib in advanced recurrent metastatic esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Utidelone (utidelone)

Snippet

Sponsor: Peking University | Conditions: Esophageal Cancer | Phase 2 | Status: UNKNOWN